For Sales
From
Description
An Edmonton region medical technology company, GLC Medical Inc., recently announced the completion of their newly developed technology, the GLCM Biosensor Test Platform.
The test requires a quick oral examination with a biosensor that can diagnose a variety of health conditions beyond the COVID-19 virus. Tuberculosis, RSV, HIV, Malaria, Zika, and Ebola are some potential viruses GLCM’s technology could screen.
The device may even be able to screen for specific cancer indicators.
The new form of testing yields results in less time and is significantly less invasive than existing testing methods, which involve nasal swabs. The test uses electrochemical impedance spectroscopy (EIS), a method typically applied in research settings to investigate material properties and electrode reactions.